Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$252.8m

Xeris Biopharma Holdings Management

Management criteria checks 2/4

Xeris Biopharma Holdings' CEO is Paul Edick, appointed in May 2021, has a tenure of 2.92 years. total yearly compensation is $2.81M, comprised of 24.7% salary and 75.3% bonuses, including company stock and options. directly owns 1.15% of the company’s shares, worth $2.92M. The average tenure of the management team and the board of directors is 2.5 years and 2.5 years respectively.

Key information

Paul Edick

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage24.7%
CEO tenure2.9yrs
CEO ownership1.2%
Management average tenure2.5yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

CEO Compensation Analysis

How has Paul Edick's remuneration changed compared to Xeris Biopharma Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$62m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$71m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$3mUS$692k

-US$95m

Sep 30 2022n/an/a

-US$133m

Jun 30 2022n/an/a

-US$137m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$4mUS$664k

-US$123m

Sep 30 2021n/an/a

-US$94m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$80m

Dec 31 2020US$2mUS$627k

-US$91m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$4mUS$598k

-US$126m

Sep 30 2019n/an/a

-US$113m

Jun 30 2019n/an/a

-US$95m

Mar 31 2019n/an/a

-US$73m

Dec 31 2018US$1mUS$535k

-US$60m

Sep 30 2018n/an/a

-US$49m

Jun 30 2018n/an/a

-US$42m

Mar 31 2018n/an/a

-US$34m

Dec 31 2017US$1mUS$490k

-US$27m

Compensation vs Market: Paul's total compensation ($USD2.81M) is above average for companies of similar size in the US market ($USD1.60M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Edick (67 yo)

2.9yrs

Tenure

US$2,805,599

Compensation

Mr. Paul R. Edick serves as the Chief Executive Officer of Xeris Biopharma Holdings, Inc. since May 2021 in connection with the Strongbridge acquisition and has been its Chairman since 2021. He served as P...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Edick
Chairman & CEO2.9yrsUS$2.81m1.15%
$ 2.9m
John Shannon
President & COO2.5yrsUS$1.53m0.59%
$ 1.5m
Beth Hecht
Chief Legal Officer & Corporate Secretary2.5yrsUS$1.27m0.35%
$ 893.9k
Steven Pieper
Chief Financial Officer2.5yrsno data1.16%
$ 2.9m
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications5.8yrsno datano data
Kenneth Johnson
Senior VP of Global Development & Medical Affairs2.5yrsno data0.13%
$ 324.3k
Kevin McCulloch
Chief Commercial Officerno datano datano data

2.5yrs

Average Tenure

60yo

Average Age

Experienced Management: XERS's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Edick
Chairman & CEO3.3yrsUS$2.81m1.15%
$ 2.9m
John Brooks
Scientific Advisory Board Memberno datano datano data
Orville Kolterman
Member of Scientific Advisory Boardno datano datano data
Jeffrey Sherman
Independent Director2.5yrsUS$119.74k0.055%
$ 139.1k
John Schmid
Lead Independent Director2.5yrsUS$162.24k0.023%
$ 57.0k
Garheng Kong
Independent Non-Executive Director2.5yrsUS$117.24k0.051%
$ 129.0k
W. Ward
Member of Scientific Advisory Boardno datano datano data
Marla Persky
Independent Director2.5yrsUS$127.24k0.015%
$ 38.5k
Morey Haymond
Scientific Advisory Board Memberno datano datano data
John Johnson
Independent Non-Executive Director2.5yrsUS$112.24k0.50%
$ 1.3m
Barbar-Jean Bormann-Kennedy
Independent Director2.5yrsUS$127.24k0.011%
$ 27.0k
Dawn Halkuff
Independent Director2.5yrsUS$119.74k0.015%
$ 36.7k

2.5yrs

Average Tenure

66yo

Average Age

Experienced Board: XERS's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.